TCGA-CV-6937-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.142465753
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.340
- PANCREAS_BETA_CELLS+0.310
- OXIDATIVE_PHOSPHORYLATION+0.280
- KRAS_SIGNALING_DN+0.200
- NOTCH_SIGNALING+0.200
- APICAL_SURFACE+0.160
- BILE_ACID_METABOLISM+0.160
- COAGULATION+0.150
- WNT_BETA_CATENIN_SIGNALING+0.140
- FATTY_ACID_METABOLISM+0.130
Top 10 suppressed
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.560
- INTERFERON_GAMMA_RESPONSE-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- TGF_BETA_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- MITOTIC_SPINDLE-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- ALLOGRAFT_REJECTION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR25617843 | — | B | 0.849 |
| 2 | TCGA-CF-A7I0-01A-22R-A352-07 | — | — | 0.843 |
| 3 | TCGA-78-7149-01A-11R-2039-07 | — | cohortA2 | 0.836 |
| 4 | TCGA-IQ-7631-01A-11R-2081-07 | — | — | 0.836 |
| 5 | 4e06764d-9cf1-4cff-ad67-4c5e472fbff5 | — | — | 0.827 |
| 6 | s0094283 | — | — | 0.826 |
| 7 | SRR1388305 | GTEX | — | 0.824 |
| 8 | SRR25617874 | — | B | 0.816 |
| 9 | TCGA-50-5051-01A-21R-1858-07 | — | cohortA3 | 0.813 |
| 10 | TCGA-NJ-A55R-01A-11R-A262-07 | — | cohortA3 | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |